Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib versus best available therapy in ruxolitinib-treated myelofibrosis
2013-005007-13Phase 3Completed
- Sponsor
- Sierra Oncology
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mivavotinib in myelofibrosis (MF), primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF) (2 arms), sponsored by Sierra Oncology. Primary endpoint: Splenic response rate at Week 24. Started Apr 2014; status: completed.
02
Drugs
mivavotinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on 2013-005007-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005007-13.